Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8177967 | 0.98 | CYP2C19 (0.61) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL3265804 | 0.89 | CYP1A2 (0.70) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL18291998 | 0.89 | CYP2C19 (0.59) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL4719048 | 0.89 | CYP2C19 (0.59) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL1837886 | 0.85 | CYP1A2 (0.66) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL23957540 | 0.85 | CYP2C19 (0.59) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL19322388 | 0.82 | ALDH1A1 (0.67) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL31015708 | 0.82 | CYP2C19 (0.65) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL327850 | 0.82 | CYP2C19 (0.65) | CYP2C19CYP1A2CXCR4FABP1FABP6 | |
| SCHEMBL10861718 | 0.81 | CYP1A2 (0.66) | CYP2C19CYP1A2CXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20160354468-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | YEDA RES & DEV (IL) | 2016-12-08 | — | — | US | disclosed |
| US-9452172-B2 | (Bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-09-27 | — | — | US | disclosed |
| US-9074128-B2 | Metal complexes having azaborol ligands and electronic device having the same | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20140378888-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-12-25 | — | — | US | disclosed |
| US-8722898-B2 | — | — | 2014-05-13 | — | — | US | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2032141-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1202988-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-08 | — | — | EP | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001010847-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | CYP2C19 3526/4885CYP1A2 1836/4885CXCR4 1793/4885 |
| US-20140378888-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | PPOX, PPIB, PPIA | CYP2C19 3091/4885CYP1A2 4488/4885CXCR4 4870/4885 |
| US-20160354468-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | PPOX, PPIB, PPIA | CYP2C19 3159/4885CYP1A2 4476/4885CXCR4 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.